Viale, Andrea
Pettazzoni, Piergiorgio
Lyssiotis, Costas A.
Ying, Haoqiang
Sánchez, Nora
Marchesini, Matteo
Carugo, Alessandro
Green, Tessa
Seth, Sahil
Giuliani, Virginia
Kost-Alimova, Maria
Muller, Florian
Colla, Simona
Nezi, Luigi
Genovese, Giannicola
Deem, Angela K.
Kapoor, Avnish
Yao, Wantong
Brunetto, Emanuela
Kang, Ya’an
Yuan, Min
Asara, John M.
Wang, Y. Alan
Heffernan, Timothy P.
Kimmelman, Alec C.
Wang, Huamin
Fleming, Jason B.
Cantley, Lewis C.
DePinho, Ronald A.
Draetta, Giulio F.
Article History
Received: 3 May 2013
Accepted: 19 June 2014
First Online: 10 August 2014
Competing interests
: L.C.C. owns equity in, receives compensation from, and serves on the Board of Directors and Scientific Advisory Board of Agios Pharmaceuticals. Agios Pharmaceuticals is identifying metabolic pathways of cancer cells and developing drugs to inhibit such enzymes in order to disrupt tumour cell growth and survival.